Arthur m. Krieg

Q: What Schools Are Affiliated With Arthur m. Krieg

Arthur m. Krieg is affiliated with the following schools: University of Lausanne, University of Ottawa, University of California, Davis, Case Western Reserve University, University of Iowa, University of Massachusetts

Arthur m. Krieg's AcademicInfluence.com Rankings

Arthur m. Krieg

Biology

#4637

World Rank

#6894

Historical Rank

Immunology

#204

World Rank

#213

Historical Rank

biology Degrees

Download Badge

Biology

Arthur m. Krieg's Degrees

Doctorate Medicine University of Iowa
PhD Immunology University of Iowa

Why Is Arthur m. Krieg Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Arthur m. Krieg's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

CpG motifs in bacterial DNA trigger direct B-cell activation (1995) (3654)
CpG motifs in bacterial DNA and their immune effects. (2002) (2640)
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. (1996) (1532)
Therapeutic potential of Toll-like receptor 9 activation (2006) (1195)
CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity (1997) (1067)
Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 (2002) (1028)
Identification of CpG oligonucleotide sequences with high induction of IFN‐α/β in plasmacytoid dendritic cells (2001) (862)
Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. (1996) (824)
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. (1998) (722)
CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. (1999) (695)
Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1 (2004) (668)
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. (2005) (653)
Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells1 (2000) (647)
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. (2001) (630)
Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 (2000) (627)
Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities (2004) (582)
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. (1997) (569)
Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. (1998) (567)
Cutting Edge: Modulation of Airway Inflammation by CpG Oligodeoxynucleotides in a Murine Model of Asthma (1998) (548)
Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8 (2005) (546)
Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. (2009) (505)
Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. (1996) (453)
CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. (1998) (448)
Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. (1998) (431)
Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. (2001) (426)
Toll‐like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL‐12 (2001) (416)
Development of TLR9 agonists for cancer therapy. (2007) (398)
Toll-like receptor 9 (TLR9) agonists in the treatment of cancer (2008) (373)
The role of CpG motifs in innate immunity. (2000) (373)
CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. (1998) (358)
CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. (1998) (352)
Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity (2007) (342)
CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. (1998) (329)
Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. (1996) (323)
Cancer and Inflammation: Promise for Biologic Therapy (2010) (319)
Bacterial DNA-Induced NK Cell IFN-γ Production Is Dependent on Macrophage Secretion of IL-12 (1997) (306)
CpG motifs: the active ingredient in bacterial extracts? (2003) (301)
Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. (1998) (293)
Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway1 (2004) (293)
CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. (1997) (284)
Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs1 (2001) (275)
The role of CpG dinucleotides in DNA vaccines. (1998) (268)
CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. (1998) (256)
Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses1 (2008) (255)
Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. (1999) (253)
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. (2004) (251)
Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. (1998) (248)
CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. (2001) (248)
FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga (2017) (247)
Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. (1993) (230)
Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides (2004) (217)
IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. (1996) (215)
Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. (1997) (214)
Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. (1994) (212)
CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. (2000) (208)
CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults (2005) (206)
Antisense Research and Application (1998) (204)
Enhanced Dendritic Cell Maturation by TNF-α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo1 (2000) (203)
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. (2006) (202)
Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist (2004) (198)
CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. (1996) (197)
Immune effects and mechanisms of action of CpG motifs. (2000) (188)
Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. (1993) (181)
CpG still rocks! Update on an accidental drug. (2012) (179)
CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. (1999) (179)
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. (1999) (172)
Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells (2002) (172)
PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. (2013) (169)
Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in Mice (2001) (168)
New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site1 (2006) (164)
Enhancing vaccines with immune stimulatory CpG DNA. (2001) (161)
CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide (2002) (159)
Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. (1999) (157)
Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma (2006) (153)
Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. (2008) (152)
Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. (2005) (152)
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens (2001) (152)
Role of Mitogen-Activated Protein Kinases in CpG DNA-Mediated IL-10 and IL-12 Production: Central Role of Extracellular Signal-Regulated Kinase in the Negative Feedback Loop of the CpG DNA-Mediated Th1 Response1 (2002) (152)
Endogenous retroviruses: potential etiologic agents in autoimmunity (1992) (151)
CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation (2004) (150)
Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll‐like receptor 9 dependent T helper type 2 biased immune stimulation (2004) (148)
CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. (1999) (147)
CpG DNA Induces Maturation of Dendritic Cells with Distinct Effects on Nascent and Recycling MHC-II Antigen-Processing Mechanisms (2000) (143)
CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. (2003) (141)
CpG DNA Rescue from Anti-IgM-Induced WEHI-231 B Lymphoma Apoptosis via Modulation of IκBα and IκBβ and Sustained Activation of Nuclear Factor-κB/c-Rel (1998) (140)
Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. (2000) (138)
Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. (1996) (137)
An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. (1996) (135)
Mechanism of action of CpG DNA. (2000) (133)
Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. (1998) (132)
TLR9 Is Required for Protective Innate Immunity in Gram-Negative Bacterial Pneumonia: Role of Dendritic Cells (2007) (123)
CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. (2001) (122)
The Toll-Like Receptor 7 (TLR7) Agonist, Imiquimod, and the TLR9 Agonist, CpG ODN, Induce Antiviral Cytokines and Chemokines but Do Not Prevent Vaginal Transmission of Simian Immunodeficiency Virus When Applied Intravaginally to Rhesus Macaques (2005) (121)
Applied antisense oligonucleotide technology (1998) (121)
CpG DNA is an effective oral adjuvant to protein antigens in mice. (2000) (120)
Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself1 (2007) (120)
CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. (2003) (120)
Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? (1995) (117)
Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma (2007) (116)
CpG DNA: A pathogenic factor in systemic lupus erythematosus? (1995) (116)
CpG Oligodeoxynucleotides Stimulate Protective Innate Immunity against Pulmonary Klebsiella Infection1 (2004) (113)
Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients (2008) (109)
Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. (1998) (109)
Bacterial DNA and CpG–Containing Oligodeoxynucleotides Activate Cutaneous Dendritic Cells and Induce IL–12 Production: Implications for the Augmentation of Th1 Responses (1999) (107)
Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse (2009) (105)
Antiinfective applications of toll-like receptor 9 agonists. (2007) (99)
Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. (1996) (97)
Mechanisms and therapeutic applications of immune stimulatory cpG DNA. (1999) (95)
Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. (2007) (95)
Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T‐rich phosphorothiate oligodeoxynucleotides (2006) (92)
Lactoferrin Binds CpG-Containing Oligonucleotides and Inhibits Their Immunostimulatory Effects on Human B Cells1 (2001) (92)
NIH conference. Systemic lupus erythematosus. (1991) (92)
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. (2006) (91)
Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. (1991) (91)
Distinct CpG oligonucleotide sequences activate human γ δ T cells via interferon‐α/‐β (2001) (91)
A role for Toll in autoimmunity (2002) (91)
Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery (2012) (91)
CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria Vaccine (2004) (90)
Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. (1998) (90)
Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. (1997) (90)
APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells1 (2000) (89)
Negative control region at the 5' end of murine leukemia virus long terminal repeats (1989) (89)
Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. (2002) (89)
CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. (1999) (89)
A role for endogenous retroviral sequences in the regulation of lymphocyte activation. (1989) (87)
CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. (1999) (87)
Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. (1999) (86)
Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. (1999) (86)
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. (2012) (86)
Induction and Regulation of Th1-Inducing Cytokines by Bacterial DNA, Lipopolysaccharide, and Heat-Inactivated Bacteria (1999) (85)
Direct Immunologic activities of CpG DNA and implications for gene therapy (1999) (84)
Now I know my CpGs. (2001) (83)
Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs. (2002) (83)
TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. (2008) (83)
Activation of Plasmacytoid Dendritic Cells with TLR9 Agonists Initiates Invariant NKT Cell-Mediated Cross-Talk with Myeloid Dendritic Cells1 (2006) (81)
CpG-A-Induced Monocyte IFN-γ-Inducible Protein-10 Production Is Regulated by Plasmacytoid Dendritic Cell-Derived IFN-α1 (2003) (80)
Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. (2001) (79)
Theoretical and Experimental Approaches to Generalized Autoimmunity (1990) (78)
Retroviruses and autoimmunity. (1990) (78)
Toll-Like Receptor 9 Regulates the Lung Macrophage Phenotype and Host Immunity in Murine Pneumonia Caused by Legionella pneumophila (2008) (76)
A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. (2010) (74)
Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-α production through activation of NF-κB (2001) (74)
C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. (2004) (72)
Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. (1994) (70)
Exon skipping therapy for Duchenne muscular dystrophy. (2015) (69)
Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. (2002) (68)
Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. (2003) (68)
Deoxycytidyl-Deoxyguanosine Oligonucleotide Classes A, B, and C Induce Distinct Cytokine Gene Expression Patterns in Rhesus Monkey Peripheral Blood Mononuclear Cells and Distinct Alpha Interferon Responses in TLR9-Expressing Rhesus Monkey Plasmacytoid Dendritic Cells (2005) (67)
Immunostimulatory CpG Oligodeoxynucleotide Confers Protection in a Murine Model of Infection with Burkholderia pseudomallei (2004) (66)
Phagocytic antigen processing and effects of microbial products on antigen processing and T‐cell responses (1999) (65)
From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. (2001) (65)
A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. (2008) (64)
Induction of CD8 T-Cell-Specific Systemic and Mucosal Immunity against Herpes Simplex Virus with CpG-Peptide Complexes (2002) (57)
From A to Z on CpG. (2002) (56)
Impact of class A, B and C CpG‐oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus‐1 infected individuals (2007) (56)
Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. (1997) (55)
CpG oligodeoxynucleotides stimulate IFN-γ-inducible protein-10 production in human B cells (2004) (54)
NIH conference. Angioimmunoblastic lymphadenopathy with dysproteinemia. (1988) (54)
Stimulation via Toll‐like receptor 9 reduces Cryptococcus neoformans‐induced pulmonary inflammation in an IL‐12‐dependent manner (2005) (53)
Analysis of thymic endogenous retroviral expression in murine lupus. Genetic and immune studies. (1990) (52)
Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma (2018) (52)
CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both? (2003) (51)
CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. (2005) (51)
Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. (2003) (51)
Paradoxical enhancement of CD8 T cell‐dependent anti‐tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine (2007) (49)
Heterogeneous expression and coordinate regulation of endogenous retroviral sequences in human peripheral blood mononuclear cells. (1992) (49)
CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. (2003) (49)
Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). (2004) (48)
Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation (1996) (47)
Adjuvant effects of CpG oligodeoxynucleotides on responses against T‐independent type 2 antigens (2001) (47)
Antibody Repertoire Development in Fetal and Neonatal Piglets. IX. Three Pathogen-Associated Molecular Patterns Act Synergistically to Allow Germfree Piglets to Respond to Type 2 Thymus-Independent and Thymus-Dependent Antigens1 (2005) (45)
CpG DNA: a novel immunomodulator. (1999) (44)
Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON™), an Investigational Synthetic Toll-like Receptor 9 Agonist (2007) (44)
Role of endogenous retroviruses in autoimmune diseases. (1994) (44)
CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. (2001) (43)
A CpG Oligonucleotide Can Protect Mice from a Low Aerosol Challenge Dose of Burkholderia mallei (2006) (43)
Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells (2004) (43)
Direct immunologic activities of CpG DNA and implications for gene therapy. (1999) (43)
Unmethylated CpG‐containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step (1997) (43)
Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. (2001) (42)
The toll of too much TLR7. (2007) (42)
Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. (2007) (41)
CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. (2004) (41)
High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists1 (2006) (41)
Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. (2008) (40)
P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. (2003) (40)
Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. (1993) (40)
Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. (2001) (38)
CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. (2003) (38)
Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. (2006) (37)
Retroviruses and Their Roles in Chronic Inflammatory Diseases and Autoimmunity (1995) (35)
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma (2021) (35)
Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. (2005) (35)
CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. (2009) (34)
Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding. (2006) (34)
Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta. (2001) (34)
High prevalence of arthropathy in HTLV-I carriers on a Japanese island. (1996) (34)
Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ Immunization (2020) (33)
Toll-free vaccines? (2007) (33)
High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists (2006) (32)
Chronic ethanol ingestion by mice increases expression of CD80 and CD86 by activated macrophages. (2004) (32)
Immunopharmacology of CpG Oligodeoxynucleotides and Ribavirin (2004) (32)
Type I interferon is the primary regulator of inducible Ly-6C expression on T cells. (2001) (31)
Structure–Activity Relationship Studies on the Immune Stimulatory Effects of Base‐Modified CpG Toll‐Like Receptor 9 Agonists (2006) (31)
Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. (1992) (31)
Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. (2009) (31)
Oligonucleotides with novel, cationic backbone substituents: aminoethylphosphonates. (1994) (31)
Is RNAi dead? (2011) (30)
CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. (1998) (29)
Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. (2003) (29)
Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. (2011) (29)
Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen (2003) (29)
Multiple endogenous xenotropic and mink cell focus-forming murine leukemia virus-related transcripts are induced by polyclonal immune activators (1988) (28)
Immune effects and therapeutic applications of CpG motifs in bacterial DNA. (2000) (28)
Oral Pretreatment of Mice with CpG DNA Reduces Susceptibility to Oral or Intraperitoneal Challenge with Virulent Listeria monocytogenes (2003) (27)
Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. (2006) (26)
CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice (2006) (26)
Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB. (2001) (25)
Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers (2008) (24)
Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. (2006) (24)
NK cells activated in vivo by bacterial DNA control the intracellular growth of Francisella tularensis LVS. (2009) (23)
Activation of Innate Immunity in Healthy Macaca mulatta Macaques by a Single Subcutaneous Dose of GMP CpG 7909: Safety Data and Interferon-Inducible Protein-10 Kinetics for Humans and Macaques (2007) (23)
TLR9 and DNA 'feel' RAGE (2007) (22)
Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. (2002) (22)
Expression of an endogenous retroviral transcript is associated with murine lupus. (1989) (22)
Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune‐modulatory activity (2004) (22)
Association of murine lupus and thymic full-length endogenous retroviral expression maps to a bone marrow stem cell. (1991) (21)
AIMing 2 defend against intracellular pathogens (2010) (21)
A possible cause of joint destruction in septic arthritis (1999) (19)
Thrombotic thrombocytopenic purpura developing during pregnancy in a C2-deficient patient with a history of systemic lupus erythematosus. (1985) (19)
Attenuated cytokine responses in porcine lymph node cells stimulated with CpG DNA are associated with low frequency of IFNalpha-producing cells and TLR9 mRNA expression. (2008) (19)
Minding the Cs and Gs. (2000) (19)
DNA of Th 1 Responses by Immunostimulatory Role for Dendritic Cells in the Augmentation CpG-Containing Oligodeoxynucleotides : A Activation of Cutaneous Dendritic Cells by Udey and (1998) (19)
Increased expression of novel full-length endogenous mink cell focus-forming-related transcripts in autoimmune mouse strains. (1988) (18)
O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab (2020) (18)
Combination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metastatic Lewis Lung Carcinoma (LLC). (2004) (18)
Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA. (2002) (17)
Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif. (2011) (17)
Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment. (2011) (16)
Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. (1996) (16)
Signal transduction induced by immunostimulatory CpG DNA (2009) (16)
Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers (2015) (16)
Inhibition of T4 polynucleotide kinase activity by phosphorothioate and chimeric oligodeoxynucleotides. (1994) (15)
Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy (2010) (15)
Enhanced Antibody Responses Elicited by a CpG Adjuvant Do Not Improve the Protective Effect of an Aldrithiol-2-Inactivated Simian Immunodeficiency Virus Therapeutic AIDS Vaccine (2009) (14)
Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. (1997) (14)
Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides. (2004) (13)
On the quality control of antisense oligonucleotides. (1996) (13)
CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands. (2008) (13)
Endogenous secretion of IL-4 maintains growth and Thy-1 expression of a transformed B cell clone. (1993) (13)
Bacterial DNA does not increase serum corticosterone concentration or prevent increases induced by other stimuli. (2001) (12)
Interruption of a transforming growth factor alpha autocrine loop in Caco-2 cells by antisense oligodeoxynucleotides. (1995) (12)
304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma (2020) (11)
CpG ODN As a Th1 Immune Enhancer for Prophylactic and Therapeutic Vaccines (2006) (11)
AIMing 2 Detect Foreign DNA (2009) (11)
B cells express Ly-6C in a Th1 but not Th2 cytokine environment. (2002) (11)
Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs. (2010) (10)
The Toll of Cathepsin K Deficiency (2008) (10)
Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in Mice (2002) (10)
Applications of antisense oligodeoxynucleotides in immunology and autoimmunity research (1992) (10)
Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep. (2007) (10)
Targeting LDL Cholesterol With LNA (2012) (10)
TLR9-targeted CpG immunostimulatory treatment of metastatic melanoma: A phase II trial with CpG 7909 (ProMune). (2004) (9)
CpG oligonucleotides as immune adjuvants. (2000) (8)
Immune Stimulation by Oligonucleotides (2021) (8)
Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers (2009) (7)
Erratum: CPG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry (Journal of Immunology (1998) 160 (5898-5906)) (1999) (7)
The CpG motif: implications for clinical immunology. (1998) (7)
Stimulation of Toll‐Like Receptor 9 for Enhancing Vaccination (2007) (7)
Regulatory T Cells + CD 25 + Induce the Generation of CD 4 Activated by CpG Oligodeoxynucleotides Human Plasmacytoid Dendritic Cells (2004) (7)
Mechanisms and Therapeutic Applications of Immune Modulatory Oligodeoxynucleotide and Oligoribonucleotide Ligands for Toll-Like Receptors (2007) (7)
Molecular aspects of systemic lupus erythematosus: murine endogenous retroviral expression. (1992) (7)
Rescue of B cells from apoptosis by immune stimulatory CpG DNA (2009) (7)
Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant (2017) (6)
TLR9-targeted CpG immunostimulatory treatment of metastatic melanoma: A phase II trial with CpG 7909 (ProMune) (2004) (6)
Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs (1997) (6)
DNA-based immune enhancers. (2000) (6)
Abstract 1417: Combination cancer immunotherapy using checkpoint blockade and intratumoral virus-like particles containing CpG ODN (2016) (5)
PD3-1-6: PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC) (2007) (5)
TLR 8-Dependent Immune Responses Stimulating Sequence-Specific Identification of RNA Sequence Motifs (2008) (5)
Immune Effects of Bacterial DNA and Their Possible Role in the Pathogenesis of Lupus (1999) (5)
ANTISENSE AND NUCLEIC ACID-BASED THERAPEUTICS: THE NEXT MILLENNIUM (1999) (5)
Microenvironment and Immunology PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen – Speci fi c CD 8 þ T Cells Induced by Melanoma Vaccines (2014) (4)
Immunostimulatory CpG motifs and DNA vaccines. (2000) (4)
Potential use of CpG ODN for cancer immunotherapy (2006) (4)
Approach to the use of antigen non-specific immunosuppression in systemic lupus erythematosus and other rheumatic autoimmune diseases (1988) (3)
Abstract 2669: Antitumor activity of the CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models (2017) (3)
Restriction fragment length polymorphism of T cell receptor alpha and beta chain genes in patients with ankylosing spondylitis. (1988) (3)
Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10 (2021) (3)
950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma (2021) (3)
Mechanisms Recycling MHC-II Antigen-Processing Cells with Distinct Effects on Nascent and CpG DNA Induces Maturation of Dendritic (2000) (3)
CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei , Infection and Immunity (2006) (3)
Dendritic Cells Cell-Mediated Cross-Talk with Myeloid with TLR9 Agonists Initiates Invariant NKT Activation of Plasmacytoid Dendritic Cells (2006) (3)
The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays. (2013) (3)
Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides (2022) (3)
Generation of Reactive Oxygen Species Leukocytes Through the pH-Dependent CpG Motifs in Bacterial DNA Activate (1998) (3)
Timing of immunosuppression in the natural history of autoimmune diseases. (1992) (3)
Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma. (2016) (2)
Class I-Restricted T Cells Oligodeoxynucleotide Enhance Activation of APC Stimulated by CpG and (2000) (2)
Preferential nuclear compartmentalization of endogenous mink cell focus- forming-related retroviral transcripts (1990) (2)
FP03.05 TLR9 Agonist CMP-001 Plus Atezolizumab +/- Radiation Therapy in Patients With PD-1 Blockade Resistant Advanced NSCLC (2021) (2)
CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner. (2013) (2)
604 Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1–6 mouse models of hepatocellular carcinoma (2020) (2)
Toward genetically targeted research and therapeutics. (1992) (2)
A novel murine neuroblastoma vaccine strategy (2000) (2)
Role of CpG motifs in immunostimulation and gene expression (2002) (1)
Systematic Modulation of Immune Responses by CpG DNA (2001) (1)
T Cells Induced by Melanoma Vaccines + CD 8 Specific − PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen (2014) (1)
The Toll-Like Receptor 7 (TLR7) Agonist, Imiquimod, and the TLR9 Agonist, CpG ODN, Induce Antiviral Cytokinesand Chemokines but Do Not Prevent Vaginal Transmission of Simian Immunodeficiency Virus When Applied Intravaginally to RhesusMacaques (2006) (1)
Mind the gap! (2019) (1)
How to Exclude Immunostimmulatory and Other Nonantisense Effects of Antisense Oligonucleotides (1999) (1)
Applications of CpG Motifs from Bacterial DNA in Cancer Immunotherapy (2003) (1)
CpG oligodeoxynucleotide (ODN) is a potent enhancer of fractionated radiotherapy. (2004) (1)
Phase I Trial ofToll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non^Hodgkin’s Lymphoma (2007) (1)
PD-1 and Tim-3 regulate the expansion of vaccine-induced tumor antigen-specific CD8+ T cells in patients with advanced melanoma (VAC3P.944) (2014) (1)
Randomized Phase I-II Study of Vaccination With CpG 7909, Montanide ISA 720 and NY-ESO-1 Peptides for Patients With Stage III/IV Melanoma and NY-ESO-1+ Tumors: An Interim Analysis (2005) (1)
CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. (2021) (1)
Receptor 9-Dependent Pathway Murine Dendritic Cells through a Toll-Like Human Plasmacytoid Dendritic Cells and Malaria Blood Stage Parasites Activate (2004) (1)
Activation of skin-derived dendritic cells by CpG-containing oligodeoxynucleotides(ODN) with immunostimulatory activity (1998) (1)
Relationship between pre-treatment organ-specific tumor burden (TB) and response to immunotherapy in advanced melanoma (MEL). (2018) (1)
Circulation but Not in the Tumor Site T Cells in the + Melanoma-Specific CD8 New Generation Vaccine Induces Effective (2015) (1)
This information is current as Responses Established by Neonatal Priming Vaccines But May Fail to Fully Redirect Th 2 tothe Th 2 Polarization of Neonatal Responses CpG Oligodeoxynucleotides Can Circumvent (1999) (0)
Enhancement of the Anthrax AVA Vaccine with CpG ODN's (2005) (0)
A cell based vaccine strategy that enhances dendritic cell activation, migration and antigen uptake (2004) (0)
La Rosa C et al (J Infect Dis 2012; 205:1294–304) (2013) (0)
monocytogenes Listeria Intraperitoneal Challenge with Virulent Reduces Susceptibility to Oral or Oral Pretreatment of Mice with CpG DNA (2014) (0)
CpG ODN enhances anti tumor effects of capecitabine in a murine model of established renal cell carcinoma (2003) (0)
Pilot experiment for control of mosquito larvae in the field with an UV-treated preparation of bacillus thuringiensis var. israelensis (1980) (0)
Immunostimulatory oligonucleotides class c semisoft. (2005) (0)
Combination treatment of intratumoral vidutolimod (CMP-001), radiosurgery, nivolumab, and ipilimumab for metastatic colorectal carcinoma. (2023) (0)
Expanded Prospects for Oligodeoxynucleotide Drugs (2003) (0)
845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study (2022) (0)
Activation of B cells by CpG Motifs in Bacterial DNA (2002) (0)
The Journal Enters Its Third Year (1993) (0)
Expression In Vivo and Resistance to CpG DNA Induces Sustained IL-12 (1998) (0)
CpG DNA activates c-jun NH2-terminal kinase (1998) (0)
Pneumonia: Role of Dendritic Cells Immunity in Gram-Negative Bacterial TLR9 Is Required for Protective Innate (2007) (0)
A process for the preparation of nucleic acid constructs (1998) (0)
430 PLASMA LEVELS OF CD133+ MICROPARTICLES WITH DIFFERENT EXPRESSION OF ECTONUCLEOTIDASES INDICATE MAJOR HEPATIC RESECTIONS IN MICE AND HUMANS (2012) (0)
Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls. (2019) (0)
Retroviruses. Potential etiologic agents of autoimmunity (1992) (0)
Use of non-methylated CpG dinucleotide in combination with aluminum as adjuvants (1998) (0)
The Journal Continues to Develop (1991) (0)
Compositions et procedes pour formulations a base d'oligonucleotides (2007) (0)
Phase I study of immunization with the analogue peptide NY-ESO-1 157–165V in combination with CpG (PF-3512676) and Montanide ISA 720 in patients with stage III/IV melanoma (2008) (0)
Hepatitis B Surface Antigen Immunity in Mice Immunized with Recombinant CpG DNA Is a Potent Enhancer of Specific (1998) (0)
The Pendulum Swings Back (2001) (0)
Production of preparations based on Bacillus thuringiensis var. israelensis with UV-inactivated spores for the biological control of mosquito larvae. (1980) (0)
Immunostimulatory Effects on Human B Oligonucleotides and Inhibits Their Lactoferrin Binds CpG-Containing (2001) (0)
Rigging Innate Immunity against the Flu. (2017) (0)
New and old threats to human health (2001) (0)
Oligodeoxynucleotides CpG Motifs in Bacterial DNA and Synthetic Cyclosporin A Enhances IL-12 Production by (1998) (0)
Corrigendum: Toll-free vaccines? (2007) (0)
264 Strong Melan-A/MART-1 specific CD8+ T cell responses to peptide vaccination in young melanoma patients (2004) (0)
Fractionated Radiotherapy Oligodeoxynucleotides Enhances Tumor Response to Targeting Toll-like Receptor 9 with CpG (2004) (0)
Immunostimulatory oligonucleotides with combination motif with improved activity. (2002) (0)
Antisense Editorial Office to Move (2001) (0)
The Journal Reaches Its First Anniversary (1991) (0)
Primary B Cells Identified CpG DNA Motif in Human Mechanism and Function of a Newly (1999) (0)
Formulations compositions and methods for oligonucleotide (2007) (0)
Absence of p 53 mutation in Japanese patients with rheumatoid arthritis : comment on the article (0)
Th 1 Response Feedback Loop of the CpG DNA-Mediated Signal-Regulated Kinase in the Negative Production : Central Role of Extracellular CpG DNA-Mediated IL-10 and IL-12 Role of Mitogen-Activated Protein Kinases in Hong (2002) (0)
Chapter 53 – CpG Oligodeoxynucleotides for Mucosal Vaccines (2005) (0)
Antisense Is Here To Stay (1996) (0)
CpG oligodeoxynucleotides (CpG ODN) improves survival after tumor resection in an orthotopic murine model of rhabdomyosarcoma (2005) (0)
CpG Oligodeoxynucleotides and Their Potential Role in the Immunotherapy of Allergic Diseases (2002) (0)
Potential of Antisense Technology in the Treatment of Immunological Disorders (1995) (0)
MHC Class I-Restricted T Cells Oligodeoxynucleotide Enhance Activation of APC Stimulated by CpG (2000) (0)
Polytherapie associant un anticorps anti-ctla-4 et un oligodesoxynucleotide synthetique a motif cpg destinee au traitement du cancer (2006) (0)
The Journal Enters Its Second Year (1992) (0)
Methods related to interferon induced inmuoestimuladores nucleic acids. (2000) (0)
Combination motif-immunostimulatory oligonucleotides with improved effective (2002) (0)
In Vivo CpG Administration Accelerates Graft-Versus-Host Disease (GVHD) Lethality by Toll-Like Receptor 9 (TLR9) Ligation of Host Antigen-Presenting Cells (APCs) and Promotes Allogeneic Bone Marrow (BM) Rejection by TLR9 Ligation of Donor APCs. (2006) (0)
Phase 2 Study of Intratumoral Vidutolimod With Intravenous Cemiplimab in Patients With Locally Advanced or Metastatic Merkel Cell Carcinoma (CMP-001- 009) (2022) (0)
Anti-tumor applications of activating toll-like receptor 9 with PF-3512676 (Formerly CPG 7909) (2006) (0)
Uptake and Localization of Phosphodiester and Chimeric Oligodeoxynucleotides in Normal and Leukemic Primary Cells (2017) (0)
Combination Lymphoma Immunotherapy Using Checkpoint Blockade and Intratumoral Virus-like Particles Containing CpG TLR9 Agonist (2016) (0)
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC (2022) (0)
Antigen-Derived Peptide CTL Induction Against Tumor CpG Are Efficient Adjuvants for Specific (2002) (0)
Combination motif immunostimulatory oligonucleotides having improved activity (2002) (0)
Abstract LB107: Novel transcriptional signatures associated with antitumor activity in vidutolimod (vidu)-treated patients (pts) with anti-PD-1-refractory melanoma and non-small cell lung cancer (NSCLC) (2022) (0)
Molecular targeting of toll-like receptor 9 with CpG oligodeoxynucleotides (ODN) for enhancement of tumor radioresponse (2004) (0)
Clinical Development of Oligodeoxynucleotide TLR9 Agonists (2008) (0)
Role of dose intensity of TLR9 agonist CpG ODN (CPG 7909) in the treatment of metastatic murine renal cell carcinoma. (2004) (0)
Percent change in amount of IFN-α secreted by PBMC after 48 hr culture with rIFN-α (125 IU/ml) plu (2011) (0)
in the Host or in the Tumor Itself Either Oligodeoxynucleotides Requires TLR9 Lymphoma Immunotherapy with CpG (2007) (0)
CpG Motifs Distinct Effects of Oligodeoxynucleotides with Divergent Therapeutic and Immunologic (2013) (0)
Enhancement of Anti-Tumor Efficacy of Paclitaxel by CpG ODN; TLR9 Agonist in Metastatic Murine Cancer Models (2004) (0)
Five Years of Antisense—Moving Forward Into Our Sixth Year with an Expanded Editorial Focus (1996) (0)
A New Editor at Oligonucleotides (2005) (0)
the Human Plasmacytoid Dendritic Cell High Mobility Group B1 Protein Suppresses (2013) (0)
Multimeric oiloncleotid connections (2012) (0)
Through an IL-12-Dependent Pathway TractInflammation in the Lower Respiratory Minimize Lipopolysaccharide-Induced Containing Unmethylated CpG Motifs Can Bacterial DNA or Oligonucleotides (1999) (0)
Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With PD-1/PD-L1 Blockade−Resistant Advanced Non−Small Cell Lung Cancer (2022) (0)
A Special Issue: The Commercial Development of Nucleic Acids (2002) (0)
Understanding the Challenges of Nucleic Acid Therapy (1997) (0)
Macrophage Class II MHC Antigen CpG Oligodeoxynucleotides DownRegulate (1999) (0)
CD14+ cells are required for TLR7/8 ligand-induced IL-12 and IFN-γ responses in bovine blood mononuclear cells (2009) (0)
Nonspecific Immunomodulator Therapy (2005) (0)
CANCER IMMUNOTHERAPIES AND VACCINES : PIPELINE ANALYSIS AND COMPETITIVE DYNAMICS An Interview with (2007) (0)
Establishing Standards and Developing Concepts in a New Field (1991) (0)
CPG DNA promotes the maturation and function of human monocyte-derived dendritic cells (modc) via indirect effects (2000) (0)
The Manuscript Review Process (1993) (0)
Cyclosporine A enhances IL-12 production by CpG DNA (1998) (0)
Mind the gap! (2019) (0)
From Molecular Science to the Treatment of Allergy (1999) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Arthur m. Krieg?

Arthur m. Krieg is affiliated with the following schools: